Zacks Research Has Bearish Forecast for BIO FY2026 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Research analysts at Zacks Research cut their FY2026 EPS estimates for Bio-Rad Laboratories in a note issued to investors on Friday, May 22nd. Zacks Research analyst Team now anticipates that the medical research company will earn $9.42 per share for the year, down from their prior forecast of $10.32. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.42 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2027 earnings at $2.21 EPS, Q4 2027 earnings at $2.48 EPS and Q1 2028 earnings at $1.96 EPS.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The company had revenue of $592.10 million during the quarter, compared to the consensus estimate of $589.91 million. During the same period in the previous year, the company earned $2.54 earnings per share. Bio-Rad Laboratories’s quarterly revenue was up 1.1% on a year-over-year basis.

Other equities analysts also recently issued reports about the stock. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $375.00 to $300.00 in a research note on Tuesday, April 7th. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Royal Bank Of Canada assumed coverage on shares of Bio-Rad Laboratories in a research note on Friday, May 15th. They set an “outperform” rating and a $320.00 target price for the company. Weiss Ratings downgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Hold” and an average target price of $303.33.

Bio-Rad Laboratories Price Performance

BIO stock opened at $288.55 on Monday. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $343.12. The company has a market cap of $7.72 billion, a P/E ratio of 47.54 and a beta of 1.06. The firm has a 50-day moving average of $274.61 and a 200 day moving average of $292.17. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UMB Bank n.a. increased its holdings in Bio-Rad Laboratories by 24.0% in the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 40 shares during the last quarter. William B. Walkup & Associates Inc. increased its holdings in Bio-Rad Laboratories by 2.6% in the 1st quarter. William B. Walkup & Associates Inc. now owns 1,902 shares of the medical research company’s stock valued at $530,000 after acquiring an additional 48 shares during the last quarter. Cetera Investment Advisers increased its holdings in Bio-Rad Laboratories by 0.6% in the 1st quarter. Cetera Investment Advisers now owns 7,596 shares of the medical research company’s stock valued at $2,117,000 after acquiring an additional 48 shares during the last quarter. CWM LLC increased its holdings in Bio-Rad Laboratories by 26.7% in the 4th quarter. CWM LLC now owns 256 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 54 shares during the last quarter. Finally, OneDigital Investment Advisors LLC increased its holdings in Bio-Rad Laboratories by 1.9% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 2,954 shares of the medical research company’s stock valued at $828,000 after acquiring an additional 55 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.